Champions Oncology Names Rob Brainin as New CEO, Ronnie Morris to Transition to Executive Chair

Champions Oncology has appointed Rob Brainin as CEO, effective August 25, 2025. Brainin has been a board member since 2021 and succeeds Dr. Ronnie Morris, who will transition to Executive Chair. Morris has led the company since 2017 and will remain involved in strategic initiatives.

Champions Oncology has announced a significant leadership change, appointing Rob Brainin as Chief Executive Officer (CEO) effective August 25, 2025. The appointment comes after a thorough review by the company's Board of Directors, which decided to replace Dr. Ronnie Morris, who has been leading Champions Oncology since 2017.

Dr. Morris will transition to the role of Executive Chair, continuing to support the company's strategic initiatives while remaining actively involved. Rob Brainin, who has served on the Champions Oncology Board since 2021, brings over 25 years of experience in life sciences and technology. His tenure includes serving as Chief Business Officer at Veracyte, an oncology diagnostics company, and previously as CEO of Genuity Science, a company focused on genomics, data, and therapeutic discovery.

Brainin's appointment is expected to bring a fresh perspective and expertise in scaling and growing businesses built on cutting-edge science and data capabilities. The leadership transition aims to strengthen Champions Oncology's position in the rapidly evolving oncology market.

This change in leadership reflects Champions Oncology's commitment to innovation and growth, positioning the company for continued success in the fight against cancer.

References:
[1] https://www.marketscreener.com/news/champions-oncology-inc-announces-ceo-changes-effective-august-25-2025-ce7c5cded081ff25